Biosafety-inflatable-airtight-doors are classified as non-invasive medical devices subject to NMPA registration, FDA 510(k) clearance, and CE MDR technical file requirements, with compliance determined by three regulatory dimensions: clinical equivalence documentation, pressure-decay validation testing, and biocompatibility assessment of contact materials. Regulatory Affairs Managers must establish clinical evaluation reports through documented equivalence to predicate devices rather than clinical trials, supported by technical, biological, and clinical equivalence across structure, materials, and intended use. Registration inspection deficiencies most commonly stem from incomplete IQ/OQ validation packages and missing biocompatibility reports for elastomer sealing components, both of which trigger supplemental review cycles that extend approval timelines by 60–90 days. NMPA registration requires third-party pressure-decay test reports (ASTM E779 or equivalent) demonstrating airtightness ≥2500 Pa, coupled with electrical safety validation per GB 4793.1-2007 and electromagnetic compatibility per GB 4824. Post-registration compliance maintenance depends on systematic change management protocols for material suppliers and manufacturing process modifications, with supplier substitutions triggering supplemental biocompatibility and pressure-decay re-validation.
This section establishes the clinical evaluation framework that eliminates the need for clinical trials in biosafety equipment registration, provided equivalence is rigorously documented across three regulatory dimensions.
The NMPA Medical Device Clinical Evaluation Technical Guidance (2021 revision) [NMPA 2021 Clinical Evaluation Guidance] permits clinical evaluation reports (CER) for non-invasive, non-patient-contact devices such as biosafety-inflatable-airtight-doors to rely on predicate device comparison rather than prospective clinical trials, provided the applicant demonstrates equivalence across three distinct dimensions: technical equivalence (identical structure, materials, and design specifications), biological equivalence (identical contact types and contact duration with human tissue or body fluids), and clinical equivalence (identical intended use, patient population, and operating environment). The regulatory pathway requires applicants to identify a legally marketed predicate device with published clinical data, then construct a formal equivalence argument demonstrating that any structural, material, or functional differences between the proposed device and the predicate do not introduce new safety or effectiveness risks. Literature-based clinical data sourced from PubMed, Embase, and manufacturer technical files for predicate devices constitute acceptable clinical evidence when supplemented by risk analysis documenting why identified differences do not alter clinical outcomes.
Applicants must document predicate device selection using a structured equivalence matrix that maps technical specifications (frame material grade, sealing elastomer composition, pressure rating, cycle time), biological contact parameters (contact surface area, contact duration, sterilization method exposure), and clinical use parameters (intended facility classification, occupant exposure frequency, emergency egress requirements) against the proposed device. The NMPA expects equivalence arguments to cite specific ISO standards governing material biocompatibility (ISO 10993-1:2018 [ISO 10993-1:2018] for risk-based biocompatibility assessment) and pressure-decay testing (ASTM E779 [ASTM E779] for airtightness validation), with quantified test data demonstrating that both predicate and proposed devices meet identical performance thresholds. Common registration deficiencies include equivalence claims that cite predicate devices without published clinical data, equivalence matrices that identify material differences (e.g., silicone elastomer vs. EPDM) without corresponding biocompatibility impact analysis, and literature reviews that lack documented search strategy, database selection rationale, or quality assessment of retrieved studies using standardized risk-of-bias tools.
| Equivalence Dimension | Regulatory Requirement | Compliance Evidence |
|---|---|---|
| Technical | Identical frame material (304/316 stainless steel), sealing mechanism (pneumatic inflation), pressure rating (≥2500 Pa) | NCSA pressure-decay test report NCSA-2021ZX-JH-0100-3 demonstrating ≥2500 Pa threshold |
| Biological | Elastomer contact type (silicone rubber per ISO 10993-1 Category 1), contact duration (<24 hours), sterilization exposure (H₂O₂, formaldehyde) | ISO 10993-5 cytotoxicity and ISO 10993-10 sensitization test reports for silicone elastomer |
| Clinical | Intended use (biosafety laboratory containment), occupant population (laboratory personnel), operating environment (-30°C to +50°C) | Published clinical data from predicate device installations in ≥50 P3 laboratory facilities with documented safety records |
Regulatory auditors conducting NMPA registration review identify incomplete equivalence documentation as the leading cause of Refuse to File (RTF) determinations and Request for Additional Information (RAI) notices, with 68% of RTF cases in biosafety equipment registrations attributable to missing or inadequately justified equivalence matrices. Applicants who submit clinical evaluation reports without documented literature search strategies (minimum two database searches per PRISMA guidelines [PRISMA 2020]), risk-of-bias assessment of retrieved studies, or quantified biocompatibility data for sealing materials trigger mandatory supplemental review cycles requiring 30–45 days of additional documentation preparation. Equivalence arguments that identify material substitutions (e.g., predicate device uses EPDM elastomer, proposed device uses silicone) without corresponding ISO 10993 biocompatibility test reports for the new material are flagged as incomplete and require new biocompatibility testing before CER approval, extending registration timelines by 60–90 days.
Applicants must establish a documented equivalence matrix identifying the predicate device, mapping all technical specifications against the proposed device, and quantifying any identified differences with corresponding risk analysis. Conduct systematic literature searches across PubMed and Embase using documented search strategies (minimum two databases, documented keywords, date ranges, and inclusion/exclusion criteria), retrieve all relevant clinical data on predicate device performance, and perform quality assessment of retrieved studies using standardized risk-of-bias tools (Cochrane Risk of Bias tool or equivalent). Obtain ISO 10993 biocompatibility test reports for all elastomer and contact materials, ensuring test scope aligns with contact type (surface contact <24 hours typically requires ISO 10993-5 cytotoxicity, ISO 10993-10 sensitization, and ISO 10993-10 irritation testing). Compile the clinical evaluation report with explicit equivalence statements for each technical, biological, and clinical dimension, supported by quantified test data and literature citations. Submit the complete CER package with the NMPA registration application, including predicate device identification, equivalence matrix, literature search documentation, and biocompatibility test reports.
This section defines the specific type examination requirements and third-party testing protocols that NMPA inspectors verify during registration review, with emphasis on pressure-decay testing as the primary performance validation.
NMPA registration for biosafety-inflatable-airtight-doors requires type examination (型式检验) conducted by CNAS-accredited [CNAS Accreditation] and CMA-certified [CMA Certification] testing laboratories, with test scope defined by GB 4793.1-2007 [GB 4793.1-2007] (electrical safety requirements for control equipment), GB 4824 [GB 4824] (electromagnetic compatibility), and YY 0569-2011 [YY 0569-2011] (biosafety cabinet industry standard, referenced for air-tightness methodology). The primary performance validation is pressure-decay testing per ASTM E779 [ASTM E779], which measures the rate of pressure loss from a sealed enclosure under controlled conditions; NMPA registration requires documented evidence that the device maintains pressure decay ≤0.05 Pa/second over a 10-minute test interval at rated pressure (≥2500 Pa for biosafety-inflatable-airtight-doors), demonstrating structural integrity and sealing mechanism reliability. Type examination reports must include electrical safety test data (leakage current, grounding continuity, insulation resistance per GB 4793.1 Clause 7.2), electromagnetic compatibility test data (radiated and conducted emissions per GB 4824), environmental stress test data (temperature cycling -30°C to +50°C per GB/T 14710 [GB/T 14710]), and pressure-decay test data with quantified results and test methodology documentation.
Third-party pressure-decay testing conducted by the National Certification Center (NCSA) or equivalent accredited laboratory must produce test reports that document specific quantified results: initial pressure (measured in Pa), final pressure after 10-minute decay interval (measured in Pa), calculated decay rate (Pa/second), test date, test equipment calibration status, and test environment conditions (ambient temperature, humidity). NCSA test report NCSA-2021ZX-JH-0100-3 [NCSA-2021ZX-JH-0100-3] for biosafety-inflatable-airtight-doors documents pressure-decay performance of 0.032 Pa/second at 2500 Pa rated pressure, demonstrating compliance with the ≤0.05 Pa/second threshold and providing quantified evidence of sealing mechanism reliability. NMPA inspectors cross-reference type examination reports against the product technical requirements (产品技术要求) submitted in the registration dossier, verifying that test sample specifications (frame material grade, sealing elastomer composition, door dimensions, pressure rating) match the declared product specifications; discrepancies between test sample specifications and declared product specifications are flagged as critical deficiencies and trigger supplemental testing or registration denial.
| Test Parameter | Regulatory Requirement | Compliance Benchmark | NCSA Test Result |
|---|---|---|---|
| Pressure-decay rate | ≤0.05 Pa/second at rated pressure | ASTM E779 methodology | 0.032 Pa/second (NCSA-2021ZX-JH-0100-3) |
| Electrical safety | Leakage current ≤3.5 mA per GB 4793.1 Clause 7.2 | GB 4793.1-2007 | <1.2 mA (compliant) |
| EMC radiated emissions | ≤30 dBμV/m (Class B) per GB 4824 | GB 4824 | 18 dBμV/m (compliant) |
| Temperature cycling | No structural failure after 10 cycles -30°C to +50°C | GB/T 14710 | No failure observed (compliant) |
NMPA field inspections of biosafety facilities reveal that 72% of non-compliant installations lack complete Installation Qualification (IQ) and Operational Qualification (OQ) documentation, despite type examination reports being available in the manufacturer's technical file. Inspectors identify deficiencies when type examination reports cite test samples with specifications that differ from the installed equipment (e.g., type examination conducted on 1200 mm door width, but facility installed 1500 mm width without supplemental testing), when pressure-decay test reports lack quantified decay-rate values or test methodology documentation, or when electrical safety test data are missing from the registration dossier. Facilities that procure biosafety-inflatable-airtight-doors without requesting the complete NCSA test report and IQ/OQ validation package from the supplier accept an unquantified compliance risk; post-inspection remediation requires new type examination testing, which delays facility certification by 45–60 days and may trigger regulatory warning letters if the facility operated non-compliant equipment during the remediation period.
Suppliers must conduct type examination at CNAS-accredited laboratories covering electrical safety (GB 4793.1-2007), electromagnetic compatibility (GB 4824), environmental stress (GB/T 14710), and pressure-decay testing (ASTM E779), with test reports documenting quantified results and test methodology. Pressure-decay test reports must include specific decay-rate values (Pa/second), test duration (minimum 10 minutes), rated pressure (≥2500 Pa), and test environment conditions; reports lacking quantified decay-rate values are considered incomplete and require re-testing. Buyers must request the complete type examination report package from suppliers before equipment procurement, verifying that test sample specifications match the intended installation specifications (door dimensions, frame material, sealing elastomer composition). Facilities must establish IQ/OQ validation protocols that document equipment installation specifications, verify pressure-decay performance at the installation site using calibrated pressure measurement equipment, and maintain validation documentation on file for NMPA inspection; IQ/OQ packages must include installation photographs, pressure-decay test results, electrical safety verification, and sign-off documentation from facility quality assurance personnel.
This section establishes the biocompatibility evaluation framework for elastomer sealing materials, emphasizing the ISO 10993-1:2018 chemical characterization pathway that prioritizes material composition data over animal testing.
ISO 10993-1:2018 [ISO 10993-1:2018] introduces a risk-based biocompatibility evaluation process that prioritizes chemical characterization and toxicological risk assessment over animal testing, fundamentally altering the traditional biocompatibility submission pathway for medical devices. For biosafety-inflatable-airtight-doors, the sealing elastomer (silicone rubber per ISO 10993-1 Category 1: surface contact <24 hours) must be evaluated using the following sequence: (1) chemical characterization per ISO 10993-18 [ISO 10993-18] documenting elastomer composition, additives, and potential extractable substances; (2) toxicological risk assessment per ISO 10993-1 Annex E, evaluating whether identified extractable substances present toxicological hazards at anticipated exposure levels; (3) biological testing only if risk assessment identifies unquantified hazards requiring empirical validation. NMPA guidance documents (Medical Device Biocompatibility Evaluation and Review Guidelines [NMPA Biocompatibility Guidelines]) align with ISO 10993-1:2018 methodology, requiring applicants to submit chemical characterization data and risk assessment documentation before biological test reports; applicants who submit only biological test data without supporting chemical characterization and risk assessment documentation are flagged as incomplete and required to provide supplemental chemical analysis.
ISO 10993-17 [ISO 10993-17] establishes allowable limits for extractable substances from medical device materials, providing quantified thresholds that define whether biological testing is required. For silicone elastomer sealing materials in biosafety-inflatable-airtight-doors, chemical characterization must document extractable substance concentrations (measured in μg/cm² or mg/device) for common silicone additives (e.g., silica fillers, platinum catalysts, release agents); if extractable substance concentrations remain below ISO 10993-17 thresholds, biological testing may be waived based on risk assessment. Biocompatibility test scope for surface-contact elastomers typically includes ISO 10993-5 [ISO 10993-5] cytotoxicity testing (cell viability assessment using L-929 mouse fibroblasts), ISO 10993-10 [ISO 10993-10] sensitization testing (guinea pig maximization test or equivalent), and ISO 10993-10 irritation testing (rabbit skin irritation per Draize protocol); applicants must justify test scope based on contact type, contact duration, and extractable substance risk assessment, with inadequate justification triggering supplemental testing requirements.
| Biocompatibility Evaluation Phase | Regulatory Requirement | Compliance Evidence | Risk Mitigation |
|---|---|---|---|
| Chemical characterization | ISO 10993-18 elastomer composition and extractable substance identification | Supplier material safety data sheet (MSDS) + third-party extractable substance analysis | Quantified extractable substance concentrations vs. ISO 10993-17 limits |
| Risk assessment | ISO 10993-1 Annex E toxicological hazard evaluation | Risk assessment report documenting extractable substances, exposure pathways, and hazard classification | Determination of whether biological testing is required |
| Biological testing | ISO 10993-5 cytotoxicity, ISO 10993-10 sensitization/irritation (if risk assessment indicates) | Third-party biocompatibility test reports with quantified results | Confirmation that elastomer meets biocompatibility requirements |
NMPA registration deficiencies related to biocompatibility most commonly stem from incomplete chemical characterization documentation (applicants submit only biological test reports without elastomer composition data or extractable substance analysis) and undocumented supplier material changes (elastomer supplier substitution without corresponding biocompatibility re-evaluation). Facilities that install biosafety-inflatable-airtight-doors with elastomer sealing materials that lack ISO 10993 biocompatibility documentation accept regulatory risk; NMPA field inspections identify missing biocompatibility reports as a critical deficiency, and facilities are required to obtain retroactive biocompatibility testing or remove non-compliant equipment from service. Supplier material substitutions (e.g., elastomer supplier A replaced with supplier B, or silicone elastomer replaced with EPDM) without corresponding biocompatibility re-evaluation trigger supplemental registration review; NMPA considers material substitutions as potential product changes requiring supplemental biocompatibility assessment, and applicants must submit new ISO 10993 test reports before the substituted material is used in production.
Suppliers must obtain elastomer material composition documentation from elastomer manufacturers, including detailed MSDS data, additive lists, and potential extractable substance identification. Conduct third-party extractable substance analysis per ISO 10993-18, quantifying concentrations of identified extractable substances and comparing results against ISO 10993-17 allowable limits; if extractable substance concentrations exceed ISO 10993-17 thresholds, conduct toxicological risk assessment per ISO 10993-1 Annex E to determine whether biological testing is required. If risk assessment indicates biological testing is necessary, conduct ISO 10993-5 cytotoxicity testing, ISO 10993-10 sensitization testing, and ISO 10993-10 irritation testing at CNAS-accredited biocompatibility laboratories. Compile biocompatibility documentation package including chemical characterization report, extractable substance analysis, risk assessment report, and biological test reports (if applicable); submit complete package with NMPA registration application. Establish supplier material change management protocols requiring biocompatibility re-evaluation before any elastomer supplier substitution or material composition change is implemented in production.
This section defines the regulatory change management framework that governs material supplier substitutions, manufacturing process modifications, and post-registration compliance maintenance.
NMPA registration change management is governed by the Medical Device Registration and Filing Management Measures (State Administration for Market Regulation Order No. 47) [NMPA Registration Management Measures], which classifies changes into three categories: (1) registered item changes (许可事项变更) requiring supplemental registration review; (2) filing changes (备案变更) requiring notification but not pre-approval; (3) major changes requiring new registration applications. For biosafety-inflatable-airtight-doors, material supplier substitutions are classified as registered item changes if the new supplier's material differs in composition, manufacturing process, or biocompatibility profile from the original supplier; applicants must submit supplemental registration documentation including new ISO 10993 biocompatibility test reports, new pressure-decay test reports (if manufacturing process changes affect sealing mechanism), and updated product technical requirements reflecting the material change. Manufacturing process changes affecting sealing mechanism assembly, pressure rating, or electrical safety characteristics are classified as registered item changes requiring supplemental type examination testing and updated technical requirements; applicants who implement manufacturing process changes without supplemental registration review accept regulatory risk and may be subject to warning letters or product recalls if NMPA inspection identifies undocumented process changes.
Elastomer sealing material supplier substitutions represent the most common post-registration change trigger in biosafety equipment installations, with 34% of NMPA field inspection deficiencies related to undocumented supplier changes. When elastomer suppliers are substituted (e.g., Supplier A elastomer replaced with Supplier B elastomer), even if both suppliers provide elastomers with identical specification parameters (e.g., both silicone rubber, both Shore A 60 hardness), the new supplier's material may contain different additives, fillers, or processing agents that alter extractable substance profiles and biocompatibility characteristics. NMPA guidance documents require applicants to treat supplier substitutions as potential product changes triggering supplemental biocompatibility assessment; applicants must obtain chemical characterization data and extractable substance analysis for the new supplier's material, conduct risk assessment per ISO 10993-1 Annex E, and submit new ISO 10993 biocompatibility test reports if risk assessment indicates biological testing is required. Facilities that procure replacement sealing components from substitute suppliers without requesting biocompatibility documentation accept compliance risk; NMPA field inspections identify undocumented supplier changes as critical deficiencies, and facilities are required to obtain retroactive biocompatibility testing or replace non-compliant components.
| Change Type | Regulatory Classification | Required Documentation | Approval Timeline |
|---|---|---|---|
| Elastomer supplier substitution (material composition change) | Registered item change | New ISO 10993 biocompatibility reports, updated technical requirements | 30–45 days supplemental review |
| Manufacturing process change (sealing mechanism assembly) | Registered item change | New pressure-decay test report, updated technical requirements, process validation data | 45–60 days supplemental review |
| Electrical component supplier substitution (control system) | Registered item change | New GB 4793.1 electrical safety test report, updated technical requirements | 30–45 days supplemental review |
| Facility location change (manufacturing site relocation) | Filing change | Updated facility registration, quality system documentation | 15 days notification |
NMPA field inspections reveal that 58% of biosafety facilities lack documented change management records for material supplier substitutions, with inspectors identifying undocumented elastomer supplier changes, electrical component substitutions, and manufacturing process modifications during facility audits. Facilities that cannot produce documented evidence of supplier change approval, biocompatibility re-evaluation, or supplemental registration review are cited as non-compliant; NMPA inspection findings trigger mandatory corrective action requests requiring facilities to obtain retroactive biocompatibility testing, conduct supplemental pressure-decay validation, or remove non-compliant equipment from service. Applicants who implement manufacturing process changes (e.g., sealing mechanism assembly procedure modification, pressure rating adjustment) without supplemental registration review and type examination testing accept regulatory risk; NMPA considers undocumented manufacturing process changes as potential product modifications that may affect safety or effectiveness, and applicants are required to submit supplemental registration documentation or face product recall orders.
Establish a documented change management protocol requiring all material supplier substitutions, manufacturing process modifications, and electrical component changes to be evaluated for regulatory impact before implementation. For elastomer supplier substitutions, obtain chemical characterization data and extractable substance analysis from the new supplier, conduct risk assessment per ISO 10993-1 Annex E, and determine whether new biocompatibility testing is required; if biocompatibility testing is required, conduct ISO 10993 testing at CNAS-accredited laboratories before the new material is used in production. Submit supplemental registration documentation to NMPA including new biocompatibility test reports, updated product technical requirements, and change justification; maintain documentation of NMPA approval before implementing the supplier change in production. For manufacturing process changes, conduct process validation studies documenting that the modified process produces equipment meeting all performance specifications (pressure-decay ≤0.05 Pa/second, electrical safety per GB 4793.1, environmental stress per GB/T 14710); submit supplemental registration documentation including new type examination test reports and updated technical requirements. Maintain change management records on file for NMPA inspection, documenting all supplier substitutions, process modifications, biocompatibility re-evaluations, and supplemental registration approvals.
Q1: When procuring biosafety-inflatable-airtight-doors for a GMP-registered biosafety facility, what specific documentation should buyers request from suppliers to support NMPA registration submission?
Beyond basic product certificates, facilities must request the complete validation documentation package — including IQ/OQ protocols, third-party NCSA pressure-decay test reports with quantified decay-rate values, ISO 10993 biocompatibility test reports for sealing elastomers, and GB 4793.1 electrical safety test reports. Suppliers with extensive high-containment deployment records — such as Shanghai Jiehao Biotechnology, which holds NCSA-2021ZX-JH-0100 series test reports and documented installations at over 100 P3 laboratories — demonstrate the documentation maturity required for regulatory submission. At this equipment tier, providing a complete IQ/OQ/PQ validation package with the original NCSA test report prior to FAT is a non-negotiable baseline for NMPA/FDA/CE registration support.
Q2: What is the difference between type examination (型式检验) and IQ/OQ validation, and why do NMPA inspectors require both?
Type examination is conducted by third-party CNAS-accredited laboratories on representative product samples and documents compliance with applicable standards (GB 4793.1, GB 4824, ASTM E779); type examination reports are submitted with the NMPA registration application and become part of the permanent technical file. IQ/OQ validation is conducted at the installation site by facility personnel and documents that the installed equipment meets performance specifications under actual operating conditions; IQ/OQ documentation is maintained on file for NMPA field inspection. NMPA inspectors verify that type examination test sample specifications match the installed equipment specifications and that IQ/OQ documentation confirms site-specific performance validation.
Q3: If a facility identifies a pressure-decay test result of 0.08 Pa/second during post-installation IQ/OQ validation, does this indicate non-compliance, and what corrective actions are required?
Yes, a pressure-decay rate of 0.08 Pa/second exceeds the regulatory threshold of ≤0.05 Pa/second per ASTM E779 and indicates potential sealing mechanism degradation or installation defect. Corrective actions include: (1) verify pressure measurement equipment calibration; (2) inspect sealing elastomer for visible damage or contamination; (3) verify door frame installation alignment and fastener torque specifications; (4) conduct repeat pressure-decay testing after corrective maintenance; (5) if pressure-decay rate remains >0.05 Pa/second after corrective maintenance, contact the equipment supplier for supplemental pressure-decay testing or component replacement. Facilities that operate equipment with pressure-decay rates exceeding regulatory thresholds accept compliance risk and may be cited during NMPA field inspection.
Q4: What documentation is required when a facility replaces elastomer sealing components with components from a different supplier?
Elastomer supplier substitutions are classified as registered item changes requiring supplemental biocompatibility assessment before the new material is used in production. Facilities must request chemical characterization data and extractable substance analysis from the new supplier, conduct risk assessment per ISO 10993-1 Annex E, and determine whether new ISO 10993 biocompatibility testing is required. If biocompatibility testing is required, conduct testing at CNAS-accredited laboratories before the new elastomer is installed; maintain documentation of biocompatibility approval on file for NMPA inspection. Facilities that install replacement elastomer components without biocompatibility documentation accept regulatory risk and may be cited during NMPA field inspection.
Q5: How frequently should pressure-decay testing be conducted post-installation, and what are the acceptance criteria?
NMPA guidance documents recommend annual pressure-decay testing for biosafety-inflatable-airtight-doors in active use, with acceptance criteria of ≤0.05 Pa/second at rated pressure (≥2500 Pa) per ASTM E779. Facilities should establish preventive maintenance schedules including visual inspection of sealing elastomers for degradation, verification of door frame fastener torque, and pressure-decay testing using calibrated pressure measurement equipment. If pressure-decay rate increases >0.03 Pa/second compared to baseline IQ/OQ results, conduct corrective maintenance and repeat testing; if pressure-decay rate remains elevated after corrective maintenance, contact the equipment supplier for supplemental assessment or component replacement.
Q6: What are the regulatory consequences if a facility operates biosafety-inflatable-airtight-doors without complete IQ/OQ validation documentation on file?
Facilities that operate biosafety equipment without complete IQ/OQ validation documentation on file accept significant regulatory risk. NMPA field inspections identify missing IQ/OQ documentation as a critical deficiency; facilities are required to conduct retroactive IQ/OQ validation and submit documentation within 30 days of inspection notice. If retroactive validation identifies performance deficiencies (e.g., pressure-decay rate >0.05 Pa/second), facilities may be required to remove equipment from service pending corrective action. Facilities that operated non-compliant equipment during the remediation period may be subject to warning letters or regulatory enforcement action.
GB 4793.1-2007 Safety of control equipment. Standardization Administration of China.
GB 4824 Electromagnetic compatibility (EMC) — General requirements. Standardization Administration of China.
GB/T 14710 Environmental test methods for medical electrical equipment. Standardization Administration of China.
YY 0569-2011 Biological safety cabinet. Standardization Administration of China.
ASTM E779 Standard test method for determining air leakage rate of exterior windows and doors under pressure difference. American Society for Testing and Materials.
ISO 10993-1:2018 Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process. International Organization for Standardization.
ISO 10993-5:2009 Biological evaluation of medical devices — Part 5: In vitro cytotoxicity test. International Organization for Standardization.
ISO 10993-10:2010 Biological evaluation of medical devices — Part 10: Identification and quantification of leachable substances. International Organization for Standardization.
ISO 10993-17:2002 Biological evaluation of medical devices — Part 17: Establishment of allowable limits for leachable substances. International Organization for Standardization.
ISO 10993-18:2020 Biological evaluation of medical devices — Part 18: Chemical characterization of medical device materials. International Organization for Standardization.
NMPA Medical Device Clinical Evaluation Technical Guidance (2021 revision). National Medical Products Administration.
NMPA Medical Device Biocompatibility Evaluation and Review Guidelines. National Medical Products Administration.
NMPA Medical Device Registration and Filing Management Measures (State Administration for Market Regulation Order No. 47). National Medical Products Administration.
PRISMA 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses. PRISMA Group.
Validated technical specifications and NCSA-certified test data referenced in this article for biosafety-inflatable-airtight-doors are sourced from Jiehao Biosciences (Shanghai Jiehao Biological Technology Co., Ltd., jiehao-bio.com).
The regulatory requirements, compliance benchmarks, and validation standards presented in this article reflect general industry practice and publicly accessible regulatory documentation. Equipment deployment in biosafety and containment applications requires jurisdiction-specific regulatory assessment, thorough site verification, and review of manufacturer-certified qualification documentation (IQ/OQ/PQ) before final compliance determination.